Literature DB >> 8325071

A comparison of chemotherapy and radiotherapy as adjuvant treatment to surgery for esophageal carcinoma. Japanese Esophageal Oncology Group.

.   

Abstract

A cooperative, prospective randomized study to compare radiotherapy (50 Gy) or 2 courses of combination chemotherapy consisting of cisplatin (50 mg/m2) and vindesine (3 mg/m2) following curative resection was performed in 258 patients at 9 institutions between August 1985 and August 1987. In the two groups, no difference was present in the background factors such as sex, age, and the location and length of the tumor. Also, there was no difference of distribution of pT, pN, pM or p stage by the revised TNM classification of 1987. There was no significant difference in survival up to 5 years in the 2 groups. Concerning the side effects, the decrease in white blood cell and platelet counts was similar in the two groups, but elevation of blood urea nitrogen and creatinine concentrations was more marked in the group receiving chemotherapy than in the group with radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325071     DOI: 10.1378/chest.104.1.203

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

1.  Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years.

Authors:  N Ando; S Ozawa; Y Kitagawa; Y Shinozawa; M Kitajima
Journal:  Ann Surg       Date:  2000-08       Impact factor: 12.969

Review 2.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

3.  Improved surgical results in thoracic esophageal squamous cell carcinoma: a 40-year analysis of 792 patients.

Authors:  Hideaki Shimada; Hisahiro Matsubara; Shinichi Okazumi; Kaichi Isono; Takenori Ochiai
Journal:  J Gastrointest Surg       Date:  2007-09-01       Impact factor: 3.452

4.  Radiation therapy in the postoperative management of esophageal cancer.

Authors:  Salma K Jabbour; Charles R Thomas
Journal:  J Gastrointest Oncol       Date:  2010-12

5.  Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy.

Authors:  Hung-Chang Liu; Shih-Kai Hung; Charn-Jer Huang; Chung-Chu Chen; Ming-Jen Chen; Chun-Chao Chang; Cheng-Jeng Tai; Chi-Yuan Tzen; Li-Hua Lu; Yu-Jen Chen
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

Review 6.  Multimodal treatment for squamous cell esophageal cancer.

Authors:  U Fink; H J Stein; H Wilke; J D Roder; J R Siewert
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

7.  Long-term results after dissection of positive thoracic lymph nodes in patients with esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada; Shin-ichi Okazumi; Hisahiro Matsubara; Tooru Shiratori; Yasunori Akutsu; Yoshihiro Nabeya; Tooru Tanizawa; Kazuyuki Matsushita; Hideaki Hayashi; Kaichi Isono; Takenori Ochiai
Journal:  World J Surg       Date:  2007-12-07       Impact factor: 3.352

8.  Mode of lymphadenectomy and surgical outcome of upper thoracic esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada; Shinn-ichi Okazumi; Tooru Shiratori; Yasunori Akutsu; Hisahiro Matsubara
Journal:  J Gastrointest Surg       Date:  2009-01-21       Impact factor: 3.452

Review 9.  Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.

Authors:  Satoru Matsuda; Hiroya Takeuchi; Hirofumi Kawakubo; Nobutoshi Ando; Yuko Kitagawa
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-07-06       Impact factor: 1.520

Review 10.  Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis.

Authors:  Richard A Malthaner; Rebecca Ks Wong; R Bryan Rumble; Lisa Zuraw
Journal:  BMC Med       Date:  2004-09-24       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.